10 Brazilian centers in São Paulo, Brasilia, Presidente Prudente, Sao José do Rio Preto, Varginha, Salvador de Bahia, Criciùma
The Phase 3 clinical study will be enlarged to the US
MILAN, Sept. 2, 2020 /PRNewswire/ -- Brazil's Health Regulatory Agency, ANVISA, has greenlighted Dompé's REPAVID-19, Clinical Trial of Reparixin for Treatment of Severe Covid-19 Patients.
Reparixin inhibits the action of interleukin 8 (IL-8), one of the inflammatory signaling proteins that is thought to be associated with the lung injury seen in patients with SARS-CoV2 infection. Consequently, this action is aimed to be useful in the treatment of COVID-19 pneumonia patients. The treatment is based on Reparixin oral tablets 1200 mg TID till 21 days, in case of confirmed improvement after 7 days.
REPAVID-19 will enroll 48 for Phase 2, 111 for Phase 3 with severe COVID-19 pneumonia randomized 2:1 in the Phase 2, and the results will inform the study design for the Phase 3. The study involves a minimum of 10 Brazilian centers. Following successful completion of Phase 2, Dompé has prepared a rapid transition into a Phase 3 program, to begin once data from Phase 2 are positively evaluated, and to be extended to multiple US centers.
São Paulo (São Paulo) - Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina de São Paulo - Hospital Vila Nova Star
Presidente Prudente (São Paulo) - Santa Casa de Misericórdia de Presidente Prudente
Sao José do Rio Preto (São Paulo) - Faculdade de Medicina de São José do Rio Preto
Varginha (Minas Gerais) - Hospital Humanitas
Salvador (Bahia) - Hospital da Cidade - Hospital General Ernesto Simões Filho- SESAB - Hospital São Rafael. Rede D'or São Luiz
Brasilia(Distrito Federal) - Instituto D'or Pesquisa e Ensino
Criciùma (Santa Catarina) - Sociedade Literária e Caritativa Santo Agostinho - Hospital São José
About Dompé Dompé is a private, rapidly scaling global biopharmaceutical company founded in Milan, Italy. Today, Dompé employs more than 800 employees worldwide and maintains a US commercial operations hub in the San Francisco Bay Area as well as an R&D presence in Boston.